PT  - JOURNAL ARTICLE
AU  - Vinall, Maria
ED  - Keystone, Edward
TI  - 12-Week Results of a Phase 2b Dose-Ranging Study of Baricitinib (LY3009104) in Combination with Traditional DMARDs in Patients with RA
DP  - 2012 Sep 01
TA  - MD Conference Express
PG  - 13--14
VI  - 12
IP  - 9
4099  - http://mdc.sagepub.com/content/12/9/13.short
4100  - http://mdc.sagepub.com/content/12/9/13.full
AB  - Data from a Phase 2b study suggest that baricitinib, an oral JAK1/JAK2 inhibitor, is an efficacious treatment for rheumatoid arthritis when used in combination with traditional disease-modifying antirheumatic drugs.